On May 19, 2018, the "Discussion Meeting on the Clinical Trial Protocol for CHA for Injection in the Treatment of GBM Phase II/III" organized by our company (the sponsor) came to a successful conclusion.

A total of 22 experts from 9 centers, including the Institute of Materia Medica of the Chinese Academy of Medical Sciences, Beijing Tiantan Hospital, and Peking Union Medical College Hospital, put forward their opinions and views based on various data of CHA for injection. All the participating experts reached a consensus on the trial protocol.

CHA for injection is a Class 1.2 innovative drug for the treatment of gliomas, with complete independent intellectual property rights owned by  Jiuzhang Biotech. It was approved for clinical trials by the CFDA in 2013 and completed the Phase I clinical trial on September 15, 2017.